Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
2.23 EUR | -1.55% | -5.91% | -19.32% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.32% | 243M | C | ||
+49.41% | 56.95B | B- | ||
+39.41% | 40.26B | A | ||
-6.72% | 39.32B | B | ||
-5.96% | 28.37B | C | ||
+12.99% | 26.45B | B- | ||
-19.82% | 19.41B | B | ||
+32.35% | 12.54B | C+ | ||
+25.18% | 12.21B | B+ | ||
-0.08% | 12.15B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALCLS Stock
- Ratings Cellectis S.A.